Cargando…

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis

Multidrug-resistant and extensively drug-resistant tuberculosis (TB) are associated with worse treatment outcomes for patients, including higher mortality, than for drug-sensitive tuberculosis. Delamanid (OPC-67683) is a novel anti-TB medication with demonstrated activity against multidrug-resistant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Skripconoka, Vija, Danilovits, Manfred, Pehme, Lea, Tomson, Tarmo, Skenders, Girts, Kummik, Tiina, Cirule, Andra, Leimane, Vaira, Kurve, Anu, Levina, Klavdia, Geiter, Lawrence J., Manissero, Davide, Wells, Charles D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669462/ https://www.ncbi.nlm.nih.gov/pubmed/23018916 http://dx.doi.org/10.1183/09031936.00125812

Ejemplares similares

Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia
por: Stagg, Helen R., et al.
Publicado: (2016)

Multidrug-resistant Tuberculosis Detection, Latvia
por: Skenders, Girts, et al.
Publicado: (2005)

Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid
por: Wells, Charles D., et al.
Publicado: (2015)

The value of effective public tuberculosis treatment: an analysis of opportunity costs associated with multidrug resistant tuberculosis in Latvia
por: Miller, Thaddeus L, et al.
Publicado: (2013)

Building clinical trial capacity to develop a new treatment for multidrug-resistant tuberculosis
por: Tupasi, Thelma, et al.
Publicado: (2016)

Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis
por: Mallikaarjun, Suresh, et al.
Publicado: (2020)

Profile of delamanid for the treatment of multidrug-resistant tuberculosis
por: Szumowski, John D, et al.
Publicado: (2015)

Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects
por: Mallikaarjun, Suresh, et al.
Publicado: (2016)

Costs of multidrug-resistant TB treatment in Finland and Estonia affected by the 2019 WHO guidelines
por: Feuth, T., et al.
Publicado: (2021)

Drug Susceptibility Patterns in MDR-TB Patients: Challenges for Future Regimen Design. A Cross-Sectional Study
por: Stagg, Helen R., et al.
Publicado: (2015)

Bedaquiline and delamanid in the treatment of multidrug‐resistant tuberculosis: Promising but challenging
por: Li, Yang, et al.
Publicado: (2018)

Population Pharmacokinetic Analysis of Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis
por: Wang, Xiaofeng, et al.
Publicado: (2020)

Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis
por: Sasaki, Tomohiro, et al.
Publicado: (2022)

Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid
por: Pecora, Francesco, et al.
Publicado: (2021)

Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis
por: Nasiri, Mohammad Javad, et al.
Publicado: (2022)

Multidrug-resistant Tuberculosis Management in Resource-limited Settings
por: Nathanson, Eva, et al.
Publicado: (2006)

Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium tuberculosis
por: Khoshnood, Saeed, et al.
Publicado: (2021)

The Activities and Secretion of Cytokines Caused by Delamanid on Macrophages Infected by Multidrug-Resistant Mycobacterium tuberculosis Strains
por: Lyu, Xia-Li, et al.
Publicado: (2021)

Adverse Drug Reaction Monitoring in Multidrug-Resistant Tuberculosis Patients Receiving Bedaquiline and Delamanid-Based Regimen
por: Paikray, Elisha, et al.
Publicado: (2022)

Delamanid or pretomanid? A Solomonic judgement!
por: Mudde, Saskia E., et al.
Publicado: (2022)

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review
por: Migliori, Giovanni Battista, et al.
Publicado: (2017)

Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China
por: Zheng, Huiwen, et al.
Publicado: (2021)

Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective
por: Rodriguez, Carly A., et al.
Publicado: (2023)

The role of delamanid in the treatment of drug-resistant tuberculosis
por: Lewis, Joseph M, et al.
Publicado: (2015)

Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline
por: Tanneau, Lénaïg, et al.
Publicado: (2022)

Pediatric delamanid treatment for children with rifampicin-resistant TB
por: Tyeku, N., et al.
Publicado: (2022)

Delamanid Added to an Optimized Background Regimen in Children with Multidrug-Resistant Tuberculosis: Results of a Phase I/II Clinical Trial
por: Garcia-Prats, Anthony J., et al.
Publicado: (2022)

Delamanid: A new armor in combating drug-resistant tuberculosis
por: Xavier, Alphienes Stanley, et al.
Publicado: (2014)

Delamanid expanded access novel treatment of drug resistant tuberculosis
por: Rustomjee, Roxana, et al.
Publicado: (2015)

Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations
por: Hu, Minhui, et al.
Publicado: (2016)

Six-Month Response to Delamanid Treatment in MDR TB Patients
por: Hewison, Cathy, et al.
Publicado: (2017)

Early experience of delamanid in extensively drug-resistant pulmonary tuberculosis
por: Marwah, Vikas, et al.
Publicado: (2023)

Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea
por: Yang, Jeong Seong, et al.
Publicado: (2018)

Delamanid expanded access novel treatment of drug resistant tuberculosis [Corrigendum]
Publicado: (2016)

Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort( )
por: Hewison, Catherine, et al.
Publicado: (2022)

Erratum: Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea
Publicado: (2019)

New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid
por: Brigden, Grania, et al.
Publicado: (2015)

The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis
por: Patterson, Stephen, et al.
Publicado: (2016)

First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline
por: Tadolini, Marina, et al.
Publicado: (2016)

Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa
por: Mohr, Erika, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tak0t1l6kfjk4hskhtndq3orha